What question did this study set out to answer?

To summarize the clinical manifestations, risk factors, cellular mechanisms, and preventative strategies associated with doxorubicin- and anthracycline-induced cardiotoxicity.

January 1, 2015International Journal of Basic & Clinical PharmacologyOpen Access

Duxorubicin-induced cardiotoxicity

View Full Paper

Ask AI

Bookmark

Population

Cancer patients receiving anticancer treatment, specifically anthracyclines such as doxorubicin

Design

Review

Authors

MJMukund JoshiHerlev Hospital KSKuldip Singh SodhiMaharishi Markandeshwar University, Mullana RPRajesh PandeyInstitute of Management Technology

Discussion

Member takes

Implication

Dose limitation or dexrazoxane may mitigate anthracycline cardiotoxicity; leaves open prospective validation of optimal strategies.

Key Points

To summarize the clinical manifestations, risk factors, cellular mechanisms, and preventative strategies associated with doxorubicin- and anthracycline-induced cardiotoxicity.
Reviewed clinical features differentiating acute, subacute, and chronic anthracycline-induced cardiac dysfunction.
Analyzed molecular mechanisms involving oxidative stress, iron dysregulation, and cardiac myocyte apoptosis.
Evaluated clinical prevention approaches including dose-rate modification, cumulative dose limits, and pharmacological cardioprotectants.
Subacute and chronic cardiotoxicity typically presents as insidious left ventricular failure and congestive heart failure months to years following chemotherapy completion.
Cellular decline is primarily driven by reactive oxygen species generation in the presence of intracellular iron, coupled with disrupted calcium homeostasis and random cardiomyocyte apoptosis.
Limiting the cumulative anthracycline dose and co-administering the iron chelator and antioxidant dexrazoxane effectively lowers the incidence of cardiotoxicity.

Structured PICO

Population

Cancer patients receiving anticancer treatment, specifically anthracyclines such as doxorubicin

Intervention

Anthracyclines (doxorubicin)

Outcome

Cardiotoxicity (acute tachyarrhythmias, acute heart failure, and chronic left ventricular failure)safety

Anthracycline-induced cardiotoxicity remains a significant clinical problem that manifests as left ventricular failure, but can be mitigated by dose limitation and the use of dexrazoxane.

Cite This Study

Joshi et al. (2015) studied this question.

synapsesocial.com/papers/6a719927439bab0cabc39fc0 https://doi.org/10.5455/2319-2003.ijbcp20150203

View Full Paper

Ask AI

Bookmark

Duxorubicin-induced cardiotoxicity

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Duxorubicin-induced cardiotoxicity

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider